Sacituzumab tirumotecan for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 Nov 2019: Trial registered, NCT04152499
  2. 28 Feb 2020: Trial started, NCT04152499

The trials

NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

State
Under way
Phase
Phase 1 and Phase 2
People
1,410 taking part
Started
28 Feb 2020
Primary completion
30 Nov 2025
Arms
Phase I: Dose Escalation, Phase II: Triple Negative Breast Cancer, Phase II: Epithelial Ovarian Cancer, Phase II: Non-Small Cell Lung Cancer, Phase II: Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Phase II: Extensive-stage Small Cell Lung Cancer, Phase II: HR+/ HER2- Breast Cancer, Phase II: Head and Neck Squamous Cell Carcinoma, Phase II: Endometrial carcinoma, Phase II: Urothelial carcinoma, Phase II: Cervical Cancer
Results
None posted
  1. 5 Nov 2019: Trial registered
  2. 28 Feb 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.